Clinical trial
Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus…
NCT00473135 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00473135 |
|---|---|
| Title | Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine |
| Official title | Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Johns Hopkins Bloomberg School of Public Health |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Dengue |
| Intervention type | Biological |
| Interventions | rDEN1delta30, Placebo |
| Enrollment | 60 |
| Start date | May 1, 2007 |
| Primary completion | Jan 1, 2010 |
| First posted | May 14, 2007 |
| Last update posted | Jan 13, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: